Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

117.27USD
29 Sep 2016
Change (% chg)

$-2.12 (-1.78%)
Prev Close
$119.39
Open
$118.88
Day's High
$119.27
Day's Low
$117.04
Volume
6,190,185
Avg. Vol
6,564,393
52-wk High
$126.07
52-wk Low
$91.76

Latest Key Developments (Source: Significant Developments)

Argentum Pharmaceuticals succeeds in starting patent cancellation trial against Janssen's Zytiga
Monday, 19 Sep 2016 11:00am EDT 

Argentum Pharmaceuticals: Argentum pharmaceuticals says succeeds in starting patent cancellation trial against janssen's zytiga . Challenges claims 1−20 of Janssen's U.S. Patent no. 8,822,438, which Orange Book states will expire in 2027 .Final decision on patentability in inter partes review is due within 1 year.  Full Article

Johnson & Johnson to buy Abbott Medical Optics for $4.325 bln
Friday, 16 Sep 2016 03:00pm EDT 

Johnson & Johnson : Johnson & Johnson announces agreement to acquire Abbott Medical Optics . Deal for $4.325 billion in cash . Transaction would be modestly accretive immediately to adjusted earnings per share . Following expected deal closing, sales will be reported in medical devices segment as a separate platform within Vision Care .Deal will include ophthalmic products in three business segments: cataract surgery, laser refractive surgery and consumer eye health.  Full Article

Abbott to sell Abbott Medical Optics to Johnson & Johnson for $4.325 bln
Friday, 16 Sep 2016 03:00pm EDT 

Abbott Laboratories : Net impact of this transaction is not expected to impact Abbott's overall targeted ongoing earnings per share in 2017. .Abbott to sell Abbott Medical Optics to Johnson & Johnson for $4.325 billion.  Full Article

Janssen receives CHMP positive opinion for Stelara (Ustekinumab)
Friday, 16 Sep 2016 09:45am EDT 

Janssen-Cilag International NV : Janssen receives CHMP positive opinion for Stelara® (Ustekinumab) recommending approval for the treatment of moderately to severely active Crohn's disease in the European Union . Following this positive opinion, a final decision from European Commission is expected later this year .Ustekinumab was generally well tolerated as an induction and maintenance therapy in all three studies.  Full Article

J&J wins dismissal of New Jersey lawsuits over talc claims - Bloomberg
Friday, 2 Sep 2016 04:04pm EDT 

:J&J wins dismissal of New Jersey lawsuits over talc claims - Bloomberg.  Full Article

Johnson & Johnson reports 15 pct passive stake in Protagonist Therapeutics - SEC filing
Friday, 19 Aug 2016 10:31am EDT 

Johnson & Johnson:Johnson & Johnson reports 15.0 pct passive stake in Protagonist Therapeutics Inc as of Aug. 16.  Full Article

Genmab to receive $15 mln in milestone payments from Janssen
Wednesday, 17 Aug 2016 03:40pm EDT 

Genmab A/S : Genmab announces submission of Supplemental Biologics License Application to FDA for daratumumab in relapsed multiple myeloma .Genmab to receive USD 15 million in milestone payments from Janssen.  Full Article

Janssen submits application to U.S. FDA to expand indication for daratumumab
Wednesday, 17 Aug 2016 03:25pm EDT 

Janssen Biotech Inc : Janssen submits application to u.s. Fda to expand indication for daratumumab (darzalex®) . Application seeks second indication for daratumumab in combination with standard of care regimens for patients with multiple myeloma .Has also submitted a request for priority review of sbla for daratumumab.  Full Article

Johnson & Johnson announces ruling related to Remicade
Wednesday, 17 Aug 2016 01:54pm EDT 

Johnson & Johnson : Johnson & Johnson announces ruling related to Remicade in the District of Massachusetts Federal Court hearing . Janssen is also continuing appeal process in proceedings related to 471 patent before U.S. Patent & Trademark office . Commercial launch of an infliximab biosimilar prior to outcome of appeals would be considered an at-risk launch .Reaffirms its sales guidance for operational sales growth for FY 2016 of 3 pct to 4 pct, notwithstanding possibility of a biosimilar launch on or after Oct. 3, 2016.  Full Article

Bristol-Myers Squibb collaborates with Johnson and Johnson for lung cancer research
Tuesday, 26 Jul 2016 06:59am EDT 

Bristol-myers Squibb Co : Bristol-Myers squibb announces new research collaboration with janssen in immuno-oncology focused on lung cancer .Myers squibb co - phase 2 clinical trial will evaluate tolerability and clinical activity of combination of these agents in nsclc patients.  Full Article

Photo

FDA approves J&J's autoimmune drug Stelara for Crohn's disease

Johnson & Johnson said on Monday that the U.S. Food and Drug Administration approved the company's blockbuster psoriasis drug, Stelara, for use in adults with Crohn's disease.